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Summary
Extracorporeal photopheresis (ECP) has been used for over 35 years in the
treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over
20 years for chronic and acute graft-versus-host disease (GvHD) and solid
organ transplant rejection. ECP for CTCL and GvHD is available at spe-
cialised centres across the UK. The lack of prospective randomised trials in
ECP led to the development of UK Consensus Statements for patient selec-
tion, treatment schedules, monitoring protocols and patient assessment cri-
teria for ECP. The recent literature has been reviewed and considered when
writing this update. Most notably, the national transition from the UVAR
XTS machine to the new CELLEX machine for ECP with dual access and
a shorter treatment time has led to relevant changes in these schedules.
This consensus statement updates the previous statement from 2007 on the
treatment of CTCL and GvHD with ECP using evidence based medicine
and best medical practise and includes guidelines for both children and
adults.
Keywords: graft-versus-host disease, cutaneous T-cell lymphoma, rejection,
extracorporeal photopheresis, treatment protocol.
Extracorporeal photopheresis (ECP) is a cell-based immuno-
modulatory therapy involving the separation of leucocyte-
rich plasma followed by ex-vivo administration of a
photosensitiser and ultraviolet A (UVA) radiation before
re-infusion. The approach was first published in 1987,
reporting the treatment of erythrodermic cutaneous T-cell
lymphoma (CTCL) in a multicentre trial (Edelson et al,
1987). The UVAR system for ECP (Therakos, Exton, PA,
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USA) was approved in the US by the Food and Drug
Administration in 1988. Since then, data have been published
on over 1000 patients with CTCL treated with ECP from
centres worldwide. Their findings have verified those
reported by Edelson et al (1987) and have cited response
rates of ~60% and complete responses (CRs) of 14–26%
(Table I).
Extracorporeal photopheresis involves three stages: (i)
leukapheresis; (ii) photoactivation with 8-methoxypsoralen
(8-MOP)/UVA; and (iii) re-infusion of buffy coat.
Closed and open ECP systems are now available for clini-
cal use. In a closed ECP system (i.e. a ‘one-step’ method),
the cell separation, drug photoactivation and re-infusion
stages are fully integrated and automated and the compo-
nents are validated for use together, tested and approved for
use with 8-MOP. There is no risk of improper reinfusion
when used according to their labelling and the risk of infec-
tion and contamination associated with the medical device
itself is low. Open ECP systems use separate devices for cell
separation and drug photoactivation (‘two-step’ methods),
which have not been validated for use together: the combina-
tion of a device approved for separation and one approved
for photoactivation is not equivalent to a device approved
for ECP. Closed systems are therefore the treatment of choice
in the UK. The closed system CELLEX (Therakos) has
recently replaced the UVAR XTS (Therakos) and is used at
all UK sites. The CELLEX has several advantages over the
UVAR XTS. Firstly, it allows double needle access, signifi-
cantly shortening treatment times (from 35 to 15 h); sec-
ondly, it allows lower body weight patients to be treated
(<40 kg), which has allowed safe expansion of paediatric uses
for ECP.
The mechanism of action of ECP in CTCL is thought to
result from 8-MOP binding covalently to DNA in separated
leucocytes leading to cell cycle arrest and apoptosis. Apop-
totic leucocytes are reintroduced into the peripheral circula-
tion and phagocytosed by antigen presenting cells, with the
production of specific tumour suppressor cells against malig-
nant lymphocytes (Edelson et al, 1987). The mechanism of
action of ECP in graft-versus-host disease (GvHD) remains
poorly understood and may be multifactorial (Marshall,
2006; Franklin et al, 2015).
Extracorporeal photopheresis is recommended therapy for
erythrodermic CTCL in the European Organisation for the
Treatment and Research in Cancer (EORTC) mycosis fun-
goides/Sezary Guidelines (Trautinger et al, 2006) and in the
Joint British Association of Dermatologists and UK Cuta-
neous Lymphoma Group guidelines, endorsed in the
Improving Outcomes Guidance in Skin Cancer by the
National Institute for Health and Care Excellence (NICE,
2006). Whilst the licensed indication in the United States is
currently restricted to treatment of skin manifestations of
CTCL (http://www.therakos.com/full-prescribing-informa
tion) ECP is used in a number of other indications, most
commonly the treatment of chronic GvHD following
allogeneic haematopoietic cell transplantation (HCT). Over
600 patients are reported to have been treated with ECP for
GvHD, with response of between 20% and 80%, which was
highest for those with cutaneous or mucous membrane
involvement. A favourable response in liver cGvHD has also
been noted.
Extracorporeal photopheresis is available in 200 medical
centres worldwide including the USA, Europe, South Amer-
ica and the Near East. ECP therapy is available at specialised
centres across the UK including London, Rotherham, Not-
tingham, Manchester, Newcastle, Glasgow, Birmingham,
Sheffield, Oxford, Cambridge, Bristol, Southampton, Liver-
pool and Belfast. All centres consider patients with erythro-
dermic CTCL and GvHD for treatment with ECP and some
centres have limited experience at treating other conditions,
such as scleroderma and solid organ transplant rejection.
In 2006 an Expert Photopheresis Group was formed with
representative clinicians from all UK sites. Whilst ECP is a
relatively mature treatment option with a substantial evi-
dence base to support its use, guidance on the appropriate
use of ECP remains scarce. Over the past 10 years there have
been several larger retrospective studies published on the use
of ECP in CTCL and GvHD, but no large prospective ran-
domised controlled trials have been undertaken.
This paper reviews the existing literature on ECP with
particular emphasis on a consensus statement for its use, effi-
cacy in CTCL, GvHD and solid organ rejection. The strength
of recommendations and quality of evidence assessment for
the various conditions are shown in Appendix S1. This infor-
mation has been utilised by the UK Photopheresis Society to
update the pre-existing consensus statements (Scarisbrick
et al, 2008; Das-Gupta et al, 2014) to produce a clinically rel-
evant consensus statement for 2016 using evidence-based
medicine and best medical practise on the appropriate use of
ECP in CTCL and GvHD, to include acute and chronic dis-
ease in both adults and children. The major updates in this
new consensus are shown in Table II. The aim of these
updates is to improve upon the existing statement to allow
the most suitable patients access to ECP using a schedule
most likely to derive benefit. This consensus statement pro-
vides standardised eligibility, assessment and treatment
strategies across the UK, to enable more accurate comparison
of treatment response between UK sites and provide founda-
tions for multicentre UK trials.
Methods
Guidelines on the use of ECP in the management of CTCL
and GvHD were identified through a literature and internet
search of relevant medical databases (e.g. PUBMED, MED-
LINE, CINAHL) as well as a targeted search of relevant pro-
fessional bodies (e.g. British Association of Dermatologists).
Key words search included extracorporeal photopheresis,
ECP, treatment CTCL, treatment cGvHD, guidelines CTCL,
and guidelines cGvHD. The databases held by the Centre for
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Table I. Summary of studies using extracorporeal photochemotherapy for the treatment of CTCL.
Study reference
Total CTCL
patients (n)
Overall
response CR PR
Median
duration
of response
(months)
Median
or mean
(range) Tx
duration
(months)
Median
or mean
(range)
number
of cycles
Median
survival
from
diagnosis
Edelson
et al (1987)
37 (erythrodermic 29) 73% (27/37) 24% (9/37) 35% (13/37)
Heald et al (1989) 32 (erythrodermic 22) 86% (19/22) 23% (5/22) 45% (10/22)
Nagatani
et al (1990)
7 43% (3/7) NK NK
Zic et al (1992) 20 55% (11/20) 25% (5/20) 30% (6/20)
Koh et al (1994) 34 (erythrodermic 31) 53% (18/34) 15% (5/34) 38% (13/34)
Prinz et al (1995) 17 (erythrodermic 3) 70% (12/17) 0% (0/17) 41% (7/17)
Stevens
et al (1996)
17 (erythrodermic) 53% (9/17) 29% (5/17) 24% (4/17)
Gottlieb et al (1996) 28 (erythrodermic NK) 71% (20/28) 25% (7/28) 46% (13/28)
Duvic et al (1996) 34 (erythrodermic 28) 50% (17/34) 18% (6/34) 32% (11/34)
Zic et al (1996) 20 (erythrodermic 3) 50% (10/20) 25% (5/20) 25% (5/20) 53
Russell-Jones
et al (1997)
19 (erythrodermic) 53% (10/19) 16% (3/19) 37% (7/19)
Konstantinow
and Balda (1997)
12 (erythrodermic 6) 67% (8/12) 8% (1/12) 42% (5/12)
Miracco
et al (1997)
7 86% (6/7) 14% (1/7) 71% (5/7)
Vonderheid
et al (1998)
36 (erythrodermic 29) 33% (12/36) 14% (5/36) 19% (7/36)
Zouboulis
et al (1998)
20 65% (13/20) NK NK
Fritz et al (1999) 17 70% (12/17) 0 (0/17) 41% (7/17)
Jiang et al (1999) 25 (erythrodermic) 80% (20/25) 20% (5/25) 60% (15/25)
Bisaccia et al (2000) 37 54% (20/37) 14% (5/37) 41% (15/37)
Crovetti et al (2000) 30 (erythrodermic 9) 73% (22/30)
66% (6/9)
33% (10/30)
33% (3/9)
40% (12/30)
33% (3/9)
Wollina et al (2000) 20 65% (13/20) 50% (10/20) 15% (3/20)
Wollina et al (2001) 14 50% (7/14) 29% (4/14) 21% (3/14)
Bouwhuis
et al (2002)
55 SS 80% (44/55) 62% (34/55) 18% (10/55)
Knobler et al (2002) 20 (erythrodermic 13) 50% (10/20)
85% (11/13)
15% (3/20)
15% (2/13)
54% (7/13)
Stevens et al (2002) 17 (SS 15) 60
Suchin et al (2002) 47 79% (37/47) 26% (12/47) 53% (25/47)
Quaglino
et al (2004)
19 63% (12/19) NK NK
de Misa et al (2005) 10 (advanced SS) 60% (6/10) 10% (1/10)
Wain et al (2005) 14 (erythrodermic)
Rao et al (2006) 16 44% (7/16) NK NK
Gasova et al (2007) 8 (2 with CTCL) 100% (2/2) NK NK 34
Tsirigotis et al (2007) 5 (SS 2) 80% (4/5) 20% (1/5) 60% (4/5)
Arulogun
et al (2008)
13 (all SS;
12 erythrodermic)
62% (8/13) 15% (2/13) 46% (6/13)
Booken et al (2010) 12 (all SS) 42% (4/12) 0% (0/12) 42% (4/12) 30 (8–64) 37 (10–75) 42 months
McGirt et al (2010) 19 (all early stage MF) 63% (12/19) 11% (2/19) 53% (10/19) 65 12 12 (2–32)
Raphael et al (2011) 21 (18 erythrodermic) 57% (12/21) 14% (3/21) 43% 64 months
Siakantaris et al (2012) 98 (all erythrodermic) 75% (73/98) 30% (29/98) 45% (44/98) 21 65 months
Knobler et al (2012) 18 patients’ 61% 28% (5/18) 29 NK NK NK
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Reviews and Dissemination at the University of York, which
collate information on existing clinical and economic guideli-
nes, were also trawled along with targeted searches of bodies
responsible for producing evidence based guidelines (e.g.,
NICE, the Agency for Healthcare Research and Quality, the
National Institutes of Health).
The UK Photopheresis Society developed the updated con-
sensus statement during two meetings over a 1-year period.
This updated consensus statement builds on previously pub-
lished consensus statements (Scarisbrick et al, 2008; Das-
Gupta et al, 2014), evidence-based reports and the expert
opinion of the group on the appropriate use of ECP. Each
centre delivering ECP was invited to comment on previously
published guidelines for patient selection criteria, treatment
schedule, monitoring protocol and patient assessment criteria
to determine efficacy of ECP. Where differences in opinion
were identified, the group were asked to agree on an appro-
priate consensus position using evidence-based medicine to
aid these decisions. A review of the safety and tolerability of
ECP was previously undertaken with no new publications so
this section has not been updated (Scarisbrick et al, 2008).
Cutaneous T-cell lymphoma
Review of literature on the use of ECP in CTCL
Review of the literature on the use of ECP in CTCL contin-
ues to indicate benefit in erythrodermic CTCL, both mycosis
fungoides (MF) and Sezary syndrome (SS). The schedule is
agreed at one cycle consisting of two consecutive treatments
Table II. Changes in the updated consensus statement.
Section Update in 2016 statement
CTCL It is recommended that the treatment schedule may be continued in patients with a complete, partial or minimal
response as opposed to treatment taper. This is in keeping with other treatments for advanced MF/SS, which
should be continued whilst a clinical benefit is derived and cessation of therapy is not recommended whilst a
response is durable. This is because there are no curative therapies for CTCL and, in some patients, durable
responses >5 years are shown with ECP, which is markedly improved compared to the median survival of
advanced stage patients around 3 years (Appendix S2)
Acute GvHD New section, with recommendations on patient selection, treatment schedule, assessment criteria and steroid taper
(Appendix S3). Literature review updated to include adults and paediatrics
Chronic GvHD Update to assessment of response using National Institutes of Health criteria (Lee et al, 2015) – Appendix S4
Solid organ transplantation New section on the use of ECP in solid organ transplantation
Technical considerations New section with the use of closed system CELLEX (Therakos, Exton, PA USA), significantly shortening treatment
times, allowing double needle access and treatment of lower body weight patients (<40 kg) low body weight is no
longer an exclusion criteria
Update on technical aspects of administration of ECP, including complications and their management
(Appendix S5)
Quality management New section setting out a modular Quality Assurance programme (Appendix S6)
CTCL, cutaneous T-cell lymphoma; ECP, extracorporeal photopheresis; GvHD, graft-versus-host disease; MF, mycosis fungoides; SS, Sezary syn-
drome.
Table I. (Continued)
Study reference
Total CTCL
patients (n)
Overall
response CR PR
Median
duration
of response
(months)
Median
or mean
(range) Tx
duration
(months)
Median
or mean
(range)
number
of cycles
Median
survival
from
diagnosis
Quaglino
et al (2013)
39 (31 erythrodermic)
14 SS
74% SS
RR 91%
41% 33% 14 635 (mean) From Dx:
92 years,
from ECP:
66 years
Weber et al (2015) 51 (all erythrodermic) 63% 32/51 16% 37% 22
Edelson et al (1987) 11 patients 64% NR NR NR 5 (1–27) 32 (3–134)
CR, complete response; CTCL, cutaneous T-cell lymphoma; Dx, diagnosis; MF, mycosis fungoides; MR, minor response (>25% improvement in
skin scores); NK, not known; NR, no response; PR, partial response (>50% improvement in skin scores); SS: Sezary syndrome; Tx, treatment.
A. Alfred et al
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every 2–4 weeks, with response rates consistently around
60%, up to 30% CRs and a median survival of 6–8 years
(Zic et al, 1996; Knobler et al, 2002). This is favourable com-
pared to median survival of 29–62 months in stage III-IV
MF/SS (Scarisbrick et al, 2015). However there may be a bias
towards selecting patients with a lower tumour burden who
have a better prognosis as these patients respond better to
ECP (Evans et al, 2001; Scarisbrick et al, 2001).
The British Association of Dermatologists and the UK
Cutaneous Lymphoma Group produced guidelines on the
management of primary CTCLs in 2003 (Whittaker et al,
2003). There has been no further update for these guidelines
nor the 2006 EORTC guidelines (Trautinger et al, 2006).
Both guidelines advise on the treatment of all stages of CTCL
from diagnosis to initial assessment and treatment according
to the stage of the disease. Both recommend ECP as a first-
line therapy for erythrodermic MF and SS along with other
forms of immunotherapy. ECP is well tolerated with minimal
side effects and is usually performed on two consecutive days
every 2–4 weeks – this schedule is continued for up to
6 months to assess response. Maintenance therapy may be
tailored according to disease response and severity. The
response rate to ECP may be increased with the addition of
immuno-modulatory therapy, such as interferon-alpha
(IFNa) or bexarotene. The UK guidelines were endorsed by
NICE Improving Outcomes Guidance (NICE, 2006).
The National Comprehensive Cancer Network guidelines,
updated annually and published online (www.nccn.org) rec-
ommend ECP in MF/SS therapy ahead of chemotherapy in
patients unresponsive to skin-directed therapy or requiring
systemic therapies due to high response rates and infrequent
toxicities. Improved responses without further toxicities are
seen in combinations with other biological agents. A pre-
ferred selection due to better responses is for treatment in
erythrodermic patients.
A comprehensive guideline produced by the European
Dermatology Forum (EDF; Knobler et al, 2014) reports on
the use of ECP for all indications. In CTCL most ECP stud-
ies have primarily included patients with advanced stages of
the disease. The following prognostic factors identified
include; a short duration of disease prior to ECP commenc-
ing, preferably <2 years; absence of bulky lymphadenopathy
or major internal organ involvement; leucocyte count
<20 9 109/l, presence of a discrete number of Sezary cells
(10–20% of mononuclear cells); natural killer cell activity
close to normal; cytotoxic T-lymphocytes close to normal
(CD8+ >15%); absence of prior intensive chemotherapy; and
plaque stage disease not covering more than 10–15% of total
skin surface.
The United States Cutaneous Lymphoma Consortium
(USCLC) Review of therapeutic options, and recommenda-
tions for treatment of SS (Olsen et al, 2011) reports on many
trials using ECP as monotherapy and in combination, with
response rates varying from 40% to 80%. Excellent response
to combination therapy of IFNa and ECP are reported in
those with SS. ECP is recommended as a first-line single
agent in SS and treatment option with IFNa, bexarotene and
methotrexate as alternatives. ECP is also recommended as
combination therapy with total skin electron therapy, bexaro-
tene, IFNa or IFNc and methotrexate. This wide range of
combinations available is representative of ECP’s relative
safety and tolerability.
A comprehensive review of ECP in MF and SS (Zic,
2015) reports on the benefit of ECP as a safe and effective
therapy either as first-line systemic therapy in erythrodermic
MF/SS or combined with IFN or bexarotene. Response rates
of 50–70% with 15–25% CRs are achieved. Responses were
highest with combinations reaching >80% with ECP, IFNa
and bexarotene. A median overall survival of 6–8 years has
been reported but needs to be proven in a trial setting. This
paper also reports on predictors of response to ECP and
states an improved response with relatively lower burden of
malignant cells in blood as designated by the percentage of
Sezary cells (32% vs. 54%), higher eosinophil count, lower
CD4:CD8 ratio (132 vs. 442) or CD4+CD26 (274% vs.
572%).
UK consensus statement on ECP in CTCL
Patient selection for ECP in CTCL patients. All patients with
erythrodermic CTCL stage III or IVA (Major Criteria) may
be considered for ECP therapy as first-line therapy. Patients
should be selected with proven peripheral blood involvement
either by molecular analysis demonstrating a peripheral
blood T-cell clone and/or circulating Sezary cells more than
10% of peripheral circulating lymphocytes and/or CD4:CD8
ratio>10 (Minor Criteria). Patients with major criteria and
one or more minor criteria are considered suitable for ECP.
This is in line with reports showing that ECP has efficacy in
erythrodermic CTCL but not those with patches and plaques
even with a peripheral blood clone (Child et al, 2004). This
criterion allows treatment of patients with a peripheral blood
clone who may not have a high peripheral blood burden, as
these patients may benefit from ECP (Zouboulis et al, 1998;
Stevens et al, 2002).
There is limited literature in early stage disease MF to
determine if this group of patients may benefit from ECP
although some centres have noted a response in these
patients (Talpur et al, 2011).
Failure or intolerance of methotrexate is not considered a
prerequisite prior to ECP therapy as efficacy is similar (Wain
et al, 2005) but may be considered as an alternative first-line
therapy in erythrodermic MF before ECP is initiated, partic-
ularly because it is a relatively inexpensive therapy with a
once weekly oral dose. However, in SS, ECP is preferred over
methotrexate due to improved responses in blood for those
with leukaemic disease. Bone marrow and/or liver toxicity
may occur with methotrexate and patients require regular
follow-up. The National Patient Safety Agency have recently
made changes to the prescribing of methotrexate including
UK Photopheresis Society: ECP Consensus Statement Update
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the compulsory holding of a methotrexate record, which may
alter prescribing patterns.
Patients should be excluded from ECP therapy if they are
photosensitive, have a sensitivity to psoralen compounds
such as 8-MOP or suffer aphakia, because of the significantly
increased risk of retinal damage due to the absence of lenses.
Unlike UVAR XTS, the CELLEX machine may be safely
used in low body-weight patients. We recommend children
should be considered for treatment in specialist paediatric
centres.
A history of heparin-induced thrombocytopenia is a rela-
tive contraindication as heparin is used to flush the ECP
machine but citrate may be used as an alternative. Treatment
during pregnancy is not recommended.
Treatment schedule for CTCL. One cycle every 2–4 weeks
remains the gold standard of treatment for CTCL. Despite
the benefits of more frequent cycles for aGvHD patients, this
benefit is not seen in CTCL. To document response in skin,
blood and lymph nodes a 3-monthly assessment is required
(Appendix S2). The modified Severity-Weighted Assessment
Tool (mSWAT) assessment should be performed to skin
score erythrodermic patients (Stevens et al, 2002;
Appendix S7).
Peripheral blood involvement and lymph node disease
must be assessed, as they are important indicators of
response to treatment and stage of disease. Disease progres-
sion in blood or lymph nodes should result in a similar
change to treatment protocol as disease progression in the
skin. Peripheral blood tumour burden should be measured
using lymphocyte count, CD4:CD8 ratio and Sezary cell
count. Lymph nodes may be assessed by physical examina-
tion or imaging (computed tomography or positron emission
tomography scans). Palpable lymph nodes ≥15 mm are con-
sidered clinically significant and should be investigated by
imaging and excisional lymph node biopsy for histology to
determine the ‘N’ stage and T cell receptor gene analysis.
Psychosocial disability is important in this group of
patients and can be documented using a quality of life ques-
tionnaire, such as Skindex 29 or EORTC 30. Pruritus is a fre-
quent and disabling symptom of erythrodermic CTCL and
may be monitored using a visual analogue score. A full list
of assessments to be performed is shown in Appendix S2.
Three-monthly assessments are required to monitor
patient response and detect those with disease progression so
combination or alternative therapies could be offered. The
median time for a response to ECP is 5–6 months (Edelson
et al, 1987; Duvic et al, 1996) and an early response after 6–
8 cycles may be associated with an improved long-term out-
come (Zic et al, 1996). Late responses to ECP up to
10 months after treatment has commenced have been
reported (Duvic et al, 1996).
The 3-monthly patient assessment is aimed to highlight
those with an early response and to identify those with pro-
gressive disease for combination or alternative therapy. All
patients tolerating ECP without disease progression should
receive a minimum of 6 months therapy before combination
or alternative therapy is considered.
Patient assessment criteria for CTCL. Patient assessments
should be used to determine response to treatment. A glo-
bal response assessment, as defined in the Clinical End
Points Paper (Olsen et al, 2011), should be performed
every 3 months. All responses should be determined by the
percentage change in the skin score from baseline using
mSWAT analysis. Patients with significant peripheral blood
involvement, as defined by a raised CD4:CD8 ratio or
Sezary cell count should have a blood response measured
as a percentage change since baseline. (Olsen et al, 2011).
New palpable nodes ≥15 mm should be considered disease
progression; resolution of palpable nodes should be consid-
ered a partial (some palpable nodes ≥15 mm still present)
or CR (no palpable nodes ≥15 mm). The first assessment
at 3 months should be used to determine which patients
may require combination therapy or offered an alternative
therapy. All patients commencing ECP should receive a
minimum of 6 months therapy to allow time for
responses.
Combination therapy with IFNa and/or bexarotene may
be considered in patients with stable or possibly progressive
disease. In progressive disease, the physician should consider
other treatment options (Whittaker et al, 2003; Trautinger
et al, 2006) and the decision to continue treatment should
only be made if the alternative treatment options are inferior.
Increased response rates with both IFNa and/or bexarotene
have been proven. These combinations are highly efficacious,
with response rates up to 80% particularly in those with a
high tumour burden (Gottlieb et al, 1996; Suchin et al,
2002). However, no prospective randomised trials have been
performed.
Patients with a complete, partial or minimal response to
ECP therapy should continue on the same frequency of ECP.
The mean time to maximal response in CTCL has been
reported as 10 months (Duvic et al, 1996). As with other
treatments for advanced MF/SS, ECP should be continued
whilst a clinical benefit is derived and cessation of therapy is
not recommended whilst a response is durable. This is
because there are no curative therapies for CTCL and in
some patients, durable responses >5 years are shown with
ECP, which is markedly improved compared to the median
survival of advanced stage patients (around 3 years). Relapses
of >25% in skin and blood from best response should be
treated with an increased number of treatment cycles or con-
sideration of adjuvant therapy. The median time to treat-
ment failure is 18 months (Duvic et al, 2003).
Patients without response or progressive disease despite
having received 6 months ECP plus combination therapy for
3 months should be considered for cessation of therapy or
adjuvant therapy; only where no other treatment options
exist should treatment be continued.
A. Alfred et al
292 ª 2017 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2017, 177, 287–310
ECP in GvHD
Acute GvHD (aGvHD)
Review of current guidelines for use of ECP in aGvHD. The
American Society of Blood and Marrow Transplantation has
developed recommendations for treatment of aGvHD based
on results of 29 studies evaluating products that are com-
mercially available for secondary therapy of aGvHD (Martin
et al, 2012). The review was limited to published studies
that enrolled at least 10 patients. The evaluation of 6-
month survival estimates did not support the superior
choice of any specific agent for secondary therapy of
aGvHD. Two studies with ECP were included, which
reported different rates of 6-month survival (Messina et al,
2003; Perferetti et al, 2008) Furthermore it was concluded
that even considering the evaluation of 6-month survival
estimates, CR rates and overall response rates, the available
data could not support the choice of any specific agent for
secondary therapy of aGvHD above another (Martin et al,
2012). The choice of agent for second-line therapy should
be based on the potential toxicity, physician familiarity and
experience with the agent, convenience, availability and
expense. The timing of initiation of second-line treatment
should be based on severity of GvHD and rate of progres-
sion. With regard to ECP, overall infection risks do not
appear to be increased beyond standard therapy; no signifi-
cant interactions or increased viral reactivations are noted.
They also comment on the catheter-related issues, travel
inconvenience and cost. The ECP treatment schedule rec-
ommended is 3 per week (Week 1), 2 per week (Weeks 2–
12) and 2 per 4 weeks thereafter.
A joint working group established by the Haemato-oncol-
ogy subgroup of the British Committee for Standards in
Haematology (BCSH) and the British Society for Bone Mar-
row Transplantation (BSBMT) has made recommendations
for the diagnosis and management of aGvHD (Dignan et al,
2012a) The goal of treatment is effective control of GvHD
while minimizing risk of toxicity and relapse. With regards
to second-line treatment of aGvHD, ECP along with anti-
tumour necrosis factor a (TNFa) antibodies, mammalian/
mechanistic target of rapamycin (mTOR) inhibitors,
mycophenolate mofetil (MMF) or interleukin-2 receptor
(IL2R) antibodies are suggested (Grade 2c recommendation).
ECP is noted to have an excellent safety profile with no
reports of increased infection risk or disease relapse. At the
time of publication, ECP for this indication was limited to
centres in the UK with ECP, as patients were too unwell to
travel. However outreach models have been developed for
clinically unwell patients who are unable to travel to ECP
centres (Maher et al, 2014).
The Italian Society of Hemapheresis and Cell Manipula-
tion (SIdEM) and the Italian Group for Bone Marrow Trans-
plantation (GITMO) developed consensus best practice
recommendation for the use of ECP in aGvHD and cGvHD
in adults and children (Pierelli et al, 2013). ECP is recom-
mended for aGvHD not responding to steroid and cal-
cineurin inhibitors. Better results are expected in patients
with isolated skin involvement, while the efficacy of the pro-
cedure in visceral aGvHD is less well defined.
The EDF recommend the use of ECP in patients with
aGvHD not responding to first-line therapy with corticos-
teroids at 2 mg/kg/day, defined as progression of aGvHD
after ≥3 days of corticosteroid treatment or lack of response
after ≥7 days of corticosteroids (Knobler et al, 2014).
Patients should be treated on a weekly basis, with two to
three treatments per week with cessation on achieving CR.
Review of current literature for use of ECP in aGvHD. Grei-
nix et al (2006) reported a phase II study on 59 patients with
acute steroid-refractory GvHD grades II to IV given extracor-
poreal photochemotherapy (ECP) weekly and analysed
response and long-term survival. ECP was given on two con-
secutive days at weekly intervals and stopped immediately
after achieving maximal response. Complete resolution of
GvHD was achieved in 82% of patients with cutaneous
involvement, 61% with liver involvement, and 61% with gut
involvement. Probability of survival was 59% among com-
plete responders compared to 11% in patients with incom-
plete response. Response to ECP, a shorter interval from day
0 of HSCT until the start of ECP and a shorter duration of
ECP all had significantly favourable impacts on TRM. Over-
all survival at 4 years was significantly better in complete
responders compared to those not achieving a CR (59% vs.
11%, P < 00001). Despite abrupt discontinuation of ECP
after maximal response in the phase II study, the durability
of response was not compromised. Intensification of ECP to
2–3 treatments per week on a weekly basis resulted in signifi-
cantly improved CR rates in patients with gastrointestinal
(GI) involvement (73% vs. 25%) and patients with grade IV
aGvHD (60% vs. 12%). Garban et al (2005) reported a sin-
gle-centre study of 27 patients treated with ECP for cortico-
resistant GvHD. Six courses were given during the first
3 weeks, then, after clinical evaluation, ECP was stopped if
there was CR; in cases of partial response (PR), maintenance
therapy was one course per week until CR. Nine of 12
patients with aGvHD responded to treatment. The response
rates for skin, gut and liver were 10/12 (83%), 2/5 (40%)
and 0/2 (0%). The authors suggest that ECP is better if per-
formed as soon as possible after the diagnosis of aGvHD
when there is minimal skin or gut involvement (Garban
et al, 2005).
Perfetti et al (2008) published data on 23 patients treated
with ECP for steroid-refractory aGvHD, Twelve (52%)
achieved CR: 70%, 42% and 0% of patients, with grades II,
III and IV aGvHD, respectively; CRs in the skin, liver and
gut were 66%, 27% and 40%. Patients treated within 35 days
from onset of aGvHD had higher responses (83% vs. 47%;
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P = 01) suggesting ECP should be initiated early in the
course of aGvHD.
Jagasia et al (2013) reported a multicentre comparative
analysis of ECP versus anticytokine therapy as a second-line
treatment for steroid-refractory aGvHD. Anticytokine therapy
consisted of inolimumab or etanercept. Both overall response
(CR+PR) and CR were significantly higher in the ECP group
compared with the anti-cytokine group (66% vs. 32%,
P = 0001; 54% vs. 20%, P = 0001). There was a signifi-
cantly higher efficacy of ECP compared with anti-cytokine
treatment directed at either the IL2R or TNFa pathway in
patients with steroid-refractory grade II aGvHD, along with a
significant survival advantage for patients receiving ECP. The
study was limited by the fact that the proportions of grade
III-IV aGvHD and those receiving 2 mg/kg steroids at onset
of aGvHD were higher in the anti-cytokine therapy group
compared with the ECP group. Further, there was no stan-
dardisation of ECP schedules and taper of immune suppres-
sion.
In a systematic review of studies for ECP in the treatment
of acute and chronic GvHD, aGvHD overall response rates
(ORRs) were 69% (95% confidence interval [CI], 34–95%)
(Abu-Dalle et al, 2014). The highest ORRs were for cuta-
neous GvHD, at 84% (95% CI, 75–92%), followed by GI
with 65% (95% CI, 52–78%). Rates of immunosuppression
discontinuation were 55% (95% CI, 40–70%).
Alousi et al (2015) presented data from a Phase II, ran-
domized, adaptive Bayesian design-based study. Eighty-one
patients were randomized to ECP + methylprednisolone
(MP) (51 patients) or MP alone (30 patients). Most patients
had GvHD grade II (90%) with only 10% having grade III/
IV involvement. Skin (86%) was the most commonly
involved organ followed by upper GI (22%), lower GI (22%)
and liver (10%). The ECP arm was more beneficial in
patients with skin-only aGvHD (72% vs. 57% response rate)
whereas visceral-organ involvement response rates were simi-
lar (47% vs. 43%). Patients in the ECP arm were on lower
doses of steroids by day 56 (43% vs. 30%). The ECP arm
also showed better immune recovery and higher regulatory
T-cells.
A summary of published data on the treatment regimens
and response rates using ECP in the treatment of aGvHD is
provided in Table III with data on paediatric patients given
in Table IV.
ECP in chronic GvHD
Chronic GvHD (cGvHD) remains a significant barrier to
long-term outcomes in patients undergoing allogeneic HCT
and is a leading cause of long-term mortality and morbidity
(Wingard et al, 2011; Socie & Ritz, 2014). There is an
increased incidence of cGvHD – a trend confirmed despite
controlling for factors related to donor, graft and condition-
ing regimen (Arai et al, 2015). ECP is widely used in the sec-
ond-line treatment of cGvHD. In a review of both
prospective and retrospective studies in the secondary treat-
ment of cGvHD published between 1990 and 2011, ECP was
the most frequently studied therapy (Martin et al, 2011).
Review of guidelines. A joint working group established by
the BCSH and the BSBMT (Dignan et al, 2012b) recom-
mended that ECP may be considered as a second-line treat-
ment in skin, oral or liver cGvHD. The ECP schedule should
be fortnightly-paired treatments for a minimum assessment
period of 3 months. The strength of recommendation is
Grade 1, indicating that there is confidence of the benefits
and no other immunosuppressive therapeutic modality
received a stronger recommendation for second-line therapy
Table III. Studies regarding use of extracorporeal photopheresis in acute graft-versus-host disease (adults).
Study reference Patients (n) Schedule Age (years) CR skin CR gut CR hepatic ORR Other
Ussowicz et al (2013) 8 Median: 205 Complete or
partial symptom
remission in 3
Hautmann et al (2013) 30 30% CR, 50%
PR ORR 80%
Steroids
>50%
in 83%
Perfetti et al (2008) 23 15/23 (66%) 8/20 (40% 3/11 (27%) 12/23 (52%) CR
Greinix et al (2006) 59 47/57 (82%) 9/15 (60%) 14/23 (61%)
Garban et al (2005) 12 Six treatments
over 3 weeks
followed by
consolidation
10/12 (83%) 2/5 (40%) 0/2 (0%)
Smith et al (1998) 6 0%
Dall’Amico and
Messina (2002)
14 10/14 (71%) 6/10 (60%) 4/7 (57%
Jagasia et al (2013) 38 (66%)
CR, complete response; ORR, overall response rate: PR, partial response.
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of cGvHD. ECP may be considered as a third-line option for
cGvHD involving other organs, a Grade 2 recommendation
(Grade 2 recommendations require judicious application to
individual patients).
The German/Austrian/Swiss consensus conference on sec-
ond-line treatment of cGvHD reviewed published evidence
and conducted a survey on current clinical practice in trans-
plant centres from Germany, Austria and Switzerland (Wolff
et al, 2011). ECP was recommended with C-1 grading, indi-
cating that use in second-line treatment was justified. Partic-
ular note was made of the steroid-sparing effect and excellent
safety profile. Two Italian scientific societies, SIdEM and
GITMO, joined to develop and disseminate recommenda-
tions on appropriate application of ECP treatment in
patients with GvHD (Pierelli et al, 2013). ECP is recom-
mended in both adults and paediatric patients with cGvHD,
either steroid-resistant or steroid-dependent, irrespective of
disease extent and severity. ECP could potentially allow for
steroid sparing in responding patients and is anticipated to
improve quality of life in responding patients.
Review of literature. Since the publication of the last consen-
sus statement there have been further publications regarding
the use of ECP in cGvHD (Martin et al, 2011). However
there remains a lack of high quality data due to the continu-
ing difficulty of conducting trials in cGvHD. In addition,
comparison between different studies is complicated by the
different ECP regimens used, different immune suppressive
regimens adopted and lack of consistent application of diag-
nostic and response criteria. Despite these limitations, studies
have shown consistently high ORR and a good safety profile.
There is also a suggestion that, in addition to clinical
responses, ECP may also lead to an improvement in quality
of life in cGvHD (Pierelli et al, 2013; Dignan et al, 2014).
Our literature search identified a total of 27 studies,
including 725 adult patients treated with ECP with steroid-
resistant, -intolerant, or -dependent cGvHD with at least five
patients in each study (Table V). Response rates for cuta-
neous cGvHD were available from 23 studies with a mean
response rate of 74%. Response rates for hepatic cGvHD
were reported in 15 studies with a mean response of 62%.
The mean response rate reported in four studies for ocular
GvHD was 60%. Twelve studies reported on mucosal GvHD
with a mean response rate of 62% and five studies reported a
mean response rate of 46% in relation to GI involvement.
The response rate was 46% for pulmonary cGvHD in nine
studies reported. ORRs were available from 14 studies with a
mean ORR of 68%. Pierelli et al (2013) reviewed 23 studies
reporting on 735 patients treated with ECP for steroid-resis-
tant, -intolerant, or -dependent cGvHD. Overall and CRs
were observed in 64% and 35% of cases with cutaneous
involvement and in 56% and 27% with hepatic cGvHD,
respectively. The ORR was 47–57% in oral mucosa and GI
cGvHD. High response rates, i.e. near 50%, were also
reported in children with ocular involvement.
Scarisbrick et al (2008) reported on 23 individual studies
published responses to ECP in 521 patients. The response
rate in cutaneous cGvHD was reported in 18 studies with a
mean response of 68% and CR being achieved in some
patients; response rates in the liver were reported in 10 stud-
ies with a mean response of 63% and response rates in the
mucosa were reported in nine studies with a mean response
of 63%. A multicentre prospective phase 2 randomized study
of ECP for treatment of cGvHD compared ECP plus stan-
dard versus standard therapy alone in patients with cuta-
neous manifestations of cGvHD that could not be adequately
controlled by corticosteroid treatment (Flowers et al, 2008).
The primary efficacy end point was a blinded quantitative
Table IV. Studies regarding use of extracorporeal photopheresis in acute and chronic graft-versus-host disease (paediatrics)
Study reference Patients (n) CR acute skin, n (%) CR acute liver, n (%) CR acute gut, n (%) cGvHD OR (%)
Calore et al (2015) 72 50 (78%) 10 (84%) 42 (76%) 52 (72%) Acute: 83%
Uygun et al (2015) 6 acute
4 overlap
2 chronic
3/6 (50%) 0/2 (0%) 2/4 (50%) 66%
Acute: 50%
Chronic:100%
Overlap: 75%
Bykova et al (2013) 37 chronic 26/37 (70%) Acute: 70%
Salvaneschi et al (2001) 9 acute
14 chronic
7/9 (78%) 1/3 (33%) 3/5 (60%) 9/14 (64%) Acute: 78%
Chronic: 64%
Messina et al (2003) 33 acute
44 chronic
27/33 (82%) 9/15 (60%) 15/20 (75%) 26/44 (59%) Acute: 76%
Chronic: 59%
Berger et al (2007) 15 8/12 (67) 3/4 (75) 5/7 (71)
Gonzalez Vicent et al (2010) 8 8/8 (100) 2/2 (100) 4/7 (57)
Kanold et al (2007) 12 acute
15 chronic
10/10 (100%) 6/9 (67%) 5/6 (83%) 11/15 (73%) Acute: 83%
Chronic: 70%
Perotti et al (2010) 50 acute
23 chronic
39/47 (83%) 16/24 (67%) 8/11 (73%) 16/23 (70%) Acute: 68%
Chronic: 70%
cGvHD, chronic graft-versus-host disease; CR, complete response; OR, overall response.
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comparison of per cent change from baseline in Total Skin
Score (TSS) of 10 body regions at week 12. 48/95 patients
were randomized to ECP and standard therapy and 47/95 to
standard therapy alone. The proportion of patients who had
at least a 50% reduction in steroid dose and at least a 25%
decrease from baseline in TSS was 83% in the ECP arm at
week 12 and 0% in the control arm. The non-blinded inves-
tigator assessment of skin CR or PR revealed a significant
improvement in favour of ECP, which was generally well tol-
erated. These results suggest that ECP may have a steroid-
sparing effect in the treatment of cGvHD. In this study, how-
ever, only the skin score was used to assess primary efficacy
end point and the physicians changing the immunosuppres-
sion were aware of the study assignment. A follow-up cross-
over randomized study showed progressive improvement in
cutaneous and extra-cutaneous cGvHD after a 24-week
course of ECP with a steroid-sparing effect, suggesting that
prolonged ECP is necessary for optimal therapeutic effects in
corticosteroid-refractory cGvHD patients (Greinix et al,
2011). Complete or partial skin response at week 24 was
noted in 31%. In 17% and 33% patients, a >50% reduction
in corticosteroid dose at weeks 12 and 24 was observed.
Extra cutaneous cGvHD response was highest in oral mucosa
with 70% complete and partial resolution after week 24.
Twenty-five patients with extensive, steroid-refractory
cGvHD were enrolled in a prospective trial evaluating the
efficacy of ECP in skin and visceral cGvHD (Foss et al,
2005). Twenty had improvement in cutaneous GvHD and
six had healing of oral ulcerations. Steroid-sparing or dis-
continuation of immunosuppressive medications was possi-
ble in 80% of patients. Response rates were similar between
patients receiving treatment weekly versus fortnightly and in
patients commencing ECP less than versus greater than
18 months from transplant (70% vs. 66%). Del Fante et al
(2012) reported on a 14-year experience of ECP in 102
patients with cGvHD according to the National Institutes of
Health (NIH) classification. Sixty-four had classic cGvHD,
24 had overlap cGvHD. Response was complete in 157%,
partial in 373%, minimal in 275% and absent in 196%.
ECP represented a third-line treatment for the majority of
patients and in many patients, the duration of cGvHD and
the interval between GvHD diagnosis and ECP start were
very long, suggesting that ECP can be proposed at any dis-
ease stage. No correlation was identified between response
and NIH clinical subtype, number or degree of organ
involvement. In particular, no response was seen in 13
patients with lung involvement. Couriel et al (2006) retro-
spectively evaluated 71 patients with severe cGvHD treated
with ECP. Response rate was 61% and 14 patients achieved
CR. The best responses were observed in skin, liver, oral
mucosa and eye. There was a cumulative incidence of dis-
continuation of corticosteroids at 1 year of 22% (Couriel
et al, 2006).
In a systematic analysis of prospective interventional
trials – randomised controlled trials or observational trials
– evaluating the efficacy of ECP for treatment of steroid-
refractory or steroid-dependent acute or cGvHD (Abu-
Dalle et al, 2014), the pooled ORR for cutaneous disease
was 71% (95% CI, 57–84%), GI was 62% (95% CI, 21–
94%), hepatic 58% (95% CI, 27–86%), oral mucosa 63%
(95% CI, 43–81%), 45% (95% CI, 18–74%), and pul-
monary in 15% (95% CI, 0–50%). This analysis suggests
organ-specific response appears to be higher in cutaneous,
GI, hepatic and oral mucosa, with suggestion of a very
limited role of ECP on pulmonary cGvHD. The pooled
incidence of any grade 3- or 4 adverse events from two
studies (53 patients) was 38% (95% CI, 6–78%). The
pooled rate of discontinuation of immunosuppressive ther-
apies, including corticosteroids, from three studies (54
patients) was 23% (95% CI, 7–44%). A systemic review
looking at cGvHD showed pooled response rate for skin,
liver, ocular, oral, lung, GI and musculoskeletal. Steroid-
refractory cGvHD was 74%, 68%, 60%, 72%, 48%, 53%
and 64%, respectively (Malik et al, 2014).
Steroid-sparing or reduction of other medications has
been identified as an important beneficial effect of ECP ther-
apy in patients with cGvHD, who suffer substantial immuno-
suppression-related morbidity and mortality
(Apisarnthanarax et al, 2003; Foss et al, 2005; Dignan et al,
2012c; Ussowicz et al, 2013; Ruutu et al, 2014).
Response to ECP predicts survival (Couriel et al, 2006;
Del Fante et al, 2012). In 2005, the NIH cGvHD Consensus
Response Criteria Working Group recommended several
measures to document serial evaluation of cGvHD organ
involvement (Filipovich et al, 2005). Although meant pri-
marily for standardizing clinical trials there is evidence for
use in routine clinical practice (Palmer et al, 2014).
In 2014, the working group updated its recommenda-
tions for measures and interpretation of organ and overall
responses (Lee et al, 2015). The recommendations for
assessment are based on clinician-assessed and patient-
reported signs and symptoms, the Lee cGvHD Symptom
Scale, and clinician-assessed or patient-reported global rat-
ing scales. Collaboration with sub-specialists is encouraged
for organ-specific measurements. Age-appropriate modifica-
tions of existing measures are to be used in children with
cGvHD. The 2014 NIH response measures and clinician-
reported response at 3 and 6 months correlated with subse-
quent failure-free survival in a prospective cGvHD observa-
tional trial of 575 patients, suggesting the 2014 NIH
response measures as reflective of disease activity though
not predictive of overall survival and a smaller study
showed the lung function score is sensitive to change and
is useful as a response measure (Olivieri et al, 2013; Palmer
et al, 2015). In a prospective, multicentre, observational
study, worsening of the NIH symptom-based lung score
was associated with increased mortality (Palmer et al,
2014). Another study suggests that NIH classification can
predict outcome after ECP for steroid-refractory/dependent
GvHD (Jagasia et al, 2009).
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Use of ECP in thoracic organ transplantation
Heart transplantation
Although a number of case reports had suggested benefits of
using ECP in heart transplant recipients, the first major study
to evaluate ECP in this population was a multi-centre ran-
domised controlled study published in 1998, evaluating ECP
as an adjunct to standard triple drug immunosuppression
with acute rejection episodes as the primary outcome mea-
sure (Barr et al, 1998). This study randomised 60 patients
who had undergone heart transplant in a 1:1 ratio and the
ECP group received 24 treatments in their first 6 months.
The number of acute rejection episodes was significantly
reduced in the ECP arm, with 091  10 rejection episodes
per recipient compared with 144  10 in the standard
treatment arm, P = 004. There was no effect on survival
between the two groups at either 6 or 12 months. This
pioneering study set a standard for ECP studies that has not
been reached since and gave clear evidence that addition of
ECP to standard immunosuppression can reduce the number
of acute rejection episodes after heart transplantation.
As the use of ECP on all recipients is resource intensive
and may be unnecessary, a series of small cases series were
published to explore the role of ECP in the treatment of
either severe or recurrent rejection in heart transplant recipi-
ents. Dall’Amico et al (2000) targeted 11 patients with recur-
rent acute rejection and gave 3 months of ECP therapy with
a tapering frequency of treatment. They showed a significant
reduction in the frequency of acute rejection episodes and
lowering of rejection grade. Six rejection relapses were
observed in a total follow-up of 60 months. This observa-
tional study was not randomised and so its findings,
although encouraging, should be treated with caution. Lehrer
et al (2001), treated four patients with refractory rejection of
International Society for Heart and Lung Transplantation
grades 3A to 4 with ECP on 2 consecutive days and showed
complete histological resolution of rejection in 3 of 4 recipi-
ents. The other patient’s rejection resolved with 2 further
days of ECP treatments. The authors suggest that photo-
pheresis is a safe and effective treatment for severe refractory
heart transplant rejection. In the most severe manifestation
of cardiac rejection, the recipient suffers from haemodynamic
compromise and an observational study targeted ECP to this
cohort of recipients (Kirklin et al, 2006). From a cohort of
36 patients treated with ECP for heart rejection at their cen-
tre, 12 were treated for rejection causing haemodynamic
compromise. After 3 months of ECP the risk of rejection
causing haemodynamic compromise was dramatically
reduced to that of the standard heart transplant population.
To assess the benefits of ECP in paediatric heart transplant
recipients, Carlo et al (2014) reported outcomes from 20
heart transplant recipients, all <18 years of age with a med-
ian age of 153 years, at the start of ECP. The main indica-
tion was for recurrent or severe acute rejection. The survival
after ECP was 84% at 1 year and 53% at 3 years, suggesting
poor outcomes. The authors suggest that 11 of these 20
recipients had issues with compliance and these are the ones
with the poorest outcomes. This is important as it suggests
that use of ECP without good compliance with maintenance
immunosuppression may not be protective in the paediatric
group.
Lung transplantation
Initial experience treating lung transplant recipients was
reported in 1999, when Salerno and colleagues treated eight
recipients with progressive loss of lung function after lung
transplantation (Salerno et al, 1999). Seven of these patients
had advanced bronchiolitis obliterans syndrome (BOS) stage
3. After a median of six treatments there was a stabilisation
of lung function loss in 5 of 8 recipients and no significant
complications were reported. Due to the lack of randomisa-
tion or monitoring of a control group with advanced BOS,
whether this was a true treatment effect or represented the
natural history of BOS cannot be ascertained. Villanueva
et al (2000) treated 14 BOS patients with ECP and suggested
that those (n = 8) with earlier stage disease BOS, 0-p or 1,
experienced more benefit than those with more advanced
disease in terms of stabilisation of lung function. Again, the
retrospective observational nature and small sample size lim-
its the reliability of these findings.
In 2008, a group from Zurich published a single centre
experience with ECP for BOS and recurrent acute rejection
after lung transplantation over a 10-year period (Benden
et al, 2008). Twenty-four recipients were treated; 12 for BOS
and 12 for acute rejection. The rate of loss of forced expira-
tory volume in 1 s (FEV1) and overall graft survival were
used as primary and secondary endpoints respectively in
BOS patients. In this group, FEV1 declined at 112 ml/month
before ECP and at 12 ml/month after 12 cycles of ECP
(P = 0011). Median patient survival post-ECP was 49
(range, 05–84) years. Patients with recurrent rejection expe-
rienced stabilisation. Neither group reported any ECP-related
complications.
Morrell et al (2010) reported the effects of ECP therapy
on 60 lung transplant recipients with progressive BOS treated
between 2000 and 2007. In the 6 months prior to ECP, their
rate of FEV1 loss was 116 ml/month. In the 6 months after
ECP was commenced, this had fallen to 289 ml/month,
P < 00001. The authors concluded that ECP is an effective
way to significantly reduce the rate of decline of FEV1 in
recipients with BOS.
More recently, Greer et al (2013) reported their large single
centre experience of 65 patients with Chronic Lung Allograft
Dysfunction (CLAD) treated with ECP between 2007 and
2011. In the study, patients were retrospectively allocated to a
CLAD phenotype according to the proposed new classification
system as either classical BOS, restrictive allograft syndrome
(RAS) or neutrophilic CLAD. The vast majority of those
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receiving ECP had previously failed to respond to azithromy-
cin therapy. After ECP, 35 (54%) patients either stabilised or
increased their lung function by >10% while the remaining
patients lost >10% of FEV1. In this responder group, median
survival was 401 days compared to 133 days in the non-
responders. Factors associated with being a non-responder
were rapid decline in lung function prior to ECP, the RAS
phenotype and absence of neutrophilic inflammation.
Jaksch and colleagues from Vienna, have reported a
prospective study of ECP therapy in recipients with BOS
(Jaksch et al, 2012). It was a single centre observational study
with ECP added as a therapy to those with progressive BOS
despite full conventional therapy. In a cohort of 194 recipi-
ents who developed BOS, 51 received ECP. Thirty-one
patients (61%) from the ECP group responded to treatment
and showed sustained stabilisation of lung function,
improved survival and less need for re-transplantation. Fac-
tors associated with non-responders were a diagnosis of cys-
tic fibrosis and late-onset BOS. The mechanism of action of
ECP in lung transplant recipients remains poorly understood.
Baskaran et al (2014) investigated the immunomodulatory
actions of ECP when used in recipients with BOS. In their
study, sera were collected from recipients with BOS immedi-
ately before and 6 months after ECP commenced. Changes
in titres of donor-specific antibodies, antibodies against self-
antigens (Ka1-tubulin, collagen I and V) and circulating
levels of pro-inflammatory and anti-inflammatory cytokines
were quantified. The study showed ECP was associated with
a fall in antibody titres, a reduction in pro-inflammatory
cytokine levels and increase in anti-inflammatory levels.
There was a 63% reduction in the rate of decline of lung
function after ECP in recipients with BOS.
Further evidence about the impact of CLAD phenotypes
on the effectiveness of ECP was recently reported (Del Fante
et al, 2015). In this single centre experience of 48 recipients
with CLAD, they concluded that although ECP reduced the
rate of decline in FEV1 overall it was least effective in those
with the RAS phenotype but that rapid loss of lung function
in BOS was not associated with a poor response rate.
Consensus statement for ECP in heart and lung transplanta-
tion.
• ECP has been used safely in both heart and lung transplant
recipients with very few complications and appears to be
well tolerated.
• ECP can be used as an adjunct to standard immunosup-
pression in heart transplantation and reduces the risk of
acute rejection. Evidence of clinical and cost effectiveness
of routine ECP use in improving long-term outcomes in
heart transplantation is absent.
• ECP can be used to rescue both adult and paediatric heart
transplant recipients with recurrent acute rejection or sev-
ere rejection associated with haemodynamic compromise
with a rapid response to therapy.
• ECP has been used effectively to slow the rate of lung
function loss in patients with Chronic Lung Allograft
Dysfunction (CLAD). It appears that its effectiveness is
limited to the BOS phenotype rather than the RAS phe-
notype.
• ECP has been used successfully to reduce the risk of acute
rejection in those with a history of recurrent acute rejec-
tion episodes after lung transplantation.
• Only a proportion of recipients with BOS respond to ECP
therapy and the responders show benefits in protection of
lung function and improved survival.
• More randomised controlled studies of ECP in thoracic
organ transplantation are needed before clear guidance on
when and in which patients ECP has a clinical and cost-
effective role.
Other solid organs
Graft-versus-host disease is a rare complication of solid
organ transplantation with an incidence varying between
56% and 10% following small bowel (Mazariegos et al,
2004; Andres et al, 2010) and 01–1% after liver transplant
(Kohler et al, 2008). The mortality remains high in the
setting of small bowel transplantation (Andres et al, 2010).
ECP has been reported to treat GvHD following solid
organ transplantation (Rossi et al, 2014; Houston et al,
2016). Houston et al reported the use of ECP in patients
with GvHD post-multivisceral transplant (stomach, pan-
creas, liver, small bowel and colon) as late-stage salvage
therapy (Houston et al, 2016). ECP was delivered on days
62 and 67 post-transplant, with reduction in chimerism
from 78% to 67% over 9 days but the patient succumbed
to sepsis on Day 73. Rossi et al (2014) treated GvHD fol-
lowing simultaneous pancreas–kidney (SPK) transplant,
providing seven treatments, associated with chimerism
reduction (52–13%) and survival (Rossi et al, 2014). ECP
has also been used in transplant rejection following face
(Dubernard et al, 2007), kidney (Kusztal et al, 2011) and
liver transplantation (Urbani et al, 2004). Kusztal et al
(2011) incorporated ECP prophylaxis along with immuno-
suppressive treatment in 10 patients undergoing kidney
transplantation. Addition of ECP to standard immunosup-
pression was associated with a significantly higher glomeru-
lar filtration rate at 6 months and with a significant
increase in natural regulatory T cells among CD3 cells.
Urbani et al (2007) reported a prospective study to evalu-
ate a strategy to use ECP to delay calcineurin inhibitor
therapy in patients at high risk of renal or neurological
complications. In the 36 patients evaluated there were 18
ECP patients and 18 controls. There was no statistical sig-
nificance between the groups regarding acute rejection,
renal or neurological toxicities, However, 1-, 6-, and 12-
month survival rates were significantly higher in the ECP
arm compared to control.
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Consensus statement for ECP in other solid organ transplanta-
tion.
• The use of ECP in the above transplant settings appears
undefined. Further studies are needed to base recommen-
dations regarding the role of ECP and where it fits in the
overall management of the patient.
Biomarkers in GvHD
Significant efforts have been made to identify biomarkers for
use in the diagnosis, risk stratification and prediction of
response to treatment in GvHD. Most are limited, generated
in single institutions, and are yet to be validated. The NIH
2014 Biomarker Working Group developed a consensus
statement for trials in cGvHD (Paczesny et al, 2015). The
tests for biomarkers must be cost-effective, reproducible and
accurate.
Much of the initial work has been hypothesis-driven, with
understanding of the pathophysiology of GvHD leading to
focus on certain cells, mediators and genetic polymorphisms.
More recently with the introduction of ‘omics’, screening of
samples for large numbers of proteins (Devic et al, 2014),
DNA (Petersdorf, 2013) and RNA transcripts (Ranganathan
et al, 2012) has suggested more candidates. The most
promising candidates include the numbers and activity of
different cells, particularly B cells, natural killer (NK) cells
and T regulatory cells (Tregs). Many cytokines, cytokine
receptors and chemokines involved in lymphoid homeostasis,
trafficking and activation have been proposed, including the
common gamma chain cytokines, TNFa, B-cell activating fac-
tor (BAFF, also termed TNFSF13B), CXCL10, CXCR3 and
CXCR7. Genetic polymorphisms associated with increased or
reduced cytokine production have also been studied.
Biomarkers have been reviewed in acute (Paczesny, 2013)
and chronic GvHD (Pidala et al, 2014; Kariminia et al,
2016).
Diagnosis
Some of the most promising diagnostic biomarkers are lym-
phocytes. Patients with extensive chronic GvHD tend to have
low B cell and NK cell counts and high T cell counts in
blood (Abrahamsen et al, 2005). GvHD has been associated
with lower IgM memory B cell counts (D’Orsogna et al,
2009) and CD27-positive B cells (Greinix et al, 2008). High
BAFF levels (Sarantopoulos et al, 2009) and alterations in the
B cell response to Toll-like receptor 9 (She et al, 2007) have
also been seen. Tregs are also implicated, with expression of
FOXP3, a transcriptional repressor uniquely expressed in
Tregs, reduced in patients with GvHD (Miura et al, 2004).
Possible mediators for the diagnosis of GvHD include BAFF,
CXCL9, elafin, aminopeptidase N, soluble CD13, soluble
IL2Ra, IL6 and TNFa (Tanaka et al, 1996; Rozmus et al,
2011; Kitko et al, 2014).
Risk stratification
The expression of FOXP3 and number of Tregs are nega-
tively correlated with the severity of GvHD (Li et al, 2010).
Patients with high suppression of tumorigenicity 2 (ST2)
levels at initiation of therapy are more likely to fail therapy
and die within 6 months (Vander Lugt et al, 2013). ST2
levels taken on day 28 following cord blood transplant pre-
dict the occurrence of severe GvHD (Ponce et al, 2015).
Polymorphism of the IL10 promoter gene have been associ-
ated, in a dose-dependent fashion, with both the likelihood
of developing GvHD and the length of immunosuppression
therapy required (Kim et al, 2005). Absence of TNFa 238
A allele is associated with chronic extensive GvHD (Berti-
netto et al, 2006).
Prediction of response
Tregs numbers in patients with GvHD who received IL2 was
associated with resolution of GvHD (Koreth et al, 2011). The
frequency and number of recent thymic emigrants in Tregs
normalise in resolved GvHD but remain decreased in active
disease (Mahadeo et al, 2014). Lower levels of soluble IL2Ra
are associated with therapeutic response (Fujii et al, 2008).
Consensus statement for biomarkers in ECP and GvHD.
• Despite the number of proposed biomarkers there is cur-
rently insufficient evidence to recommend the routine use
of biomarkers for the diagnosis, risk stratification or
assessment of therapy response of GvHD. Further investi-
gation, including biobanking of samples, is recommended.
Safety report on ECP
Several papers have reported on the safety profile of ECP in
the treatment of CTCL and GvHD and of more than
500 000 treatments performed worldwide since 1987, the
incidence of reported adverse events is less than 0003%. The
most common side effects are sporadic and mild, such as
nausea, fever or headache. The constant feature in all these
papers is that ECP is noted to be an extremely safe form of
therapy and significant reactions, such as vasovagal syncope,
or infections secondary to indwelling catheters are infrequent
(Perotti et al, 1999; Perotti et al, 2010; Dignan et al, 2012b).
Safety was reported in our 2007 guidelines and no relevant
additional information was identified to include here. This is
beneficial in a group of patients where alternative therapies
are highly immunosuppressive either as chemotherapy agents
in CTCL, such as methotrexate, deoxycoformycin and CHOP
(cyclophosphamide, doxorubicin, vincristine prednisone) or
immunosuppressive therapies such as prednisolone, ciclos-
porin or MMF in GvHD.
• In summary, ECP is a safe form of therapy with serious
side effects, such as sepsis, occurring infrequently, which is
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extremely valuable in patients where alternative treatments
are highly toxic.
Quality management
The governance arrangements for apheresis procedures
including ECP have been the subject of recent National and
European guidance publications (Societa Italiana di Emafer-
esi e Manipolazione Cellulare & International Foundation for
Hemapheresis and Innovative Therapies and Diagnostics,
2014; Howell et al, 2015). There are approximately 10 000
ECP treatments per year in the UK, performed in a variety
of clinical settings and specialty departments. Whilst the
majority of therapeutic apheresis is performed in large units,
ECP may be sited in units that are not routinely performing
other therapeutic apheresis. As a consequence it is important
that the general principles of safe and effective apheresis are
followed.
The predominant indication for ECP is the second-line
management of GvHD and, as such, the delivery of an ECP
service has been included in the FACT (Foundation for the
Accreditation of Cellular Therapy)-JACIE (Joint Accredita-
tion Committee for the ISCT [International Society for Cel-
lular Therapy] and EBMT [European Group for Blood and
Marrow Transplantation]) quality standard recommendations
for HCT units, and therefore any ECP unit treating this
patient group would be expected to meet these standards
(FACT-Jacie, 2014). An ECP service should have a Quality
Assurance programme, with regular documented oversight
(Appendix S6).
Conclusions
The literature supports ECP as an effective therapy in CTCL
and acute and chronic GvHD in the adult and paediatric set-
ting. Most countries only provide ECP in specialised centres
allowing expertise to develop, in keeping with NICE guide-
lines. We have used evidence-based medicine and best medi-
cal practise of our UK Photopheresis Society (UKPS) group
to update the 2007 Consensus Statement for patient selec-
tion, treatment schedule, monitoring and assessment of ECP
therapy in CTCL and GvHD and solid organ rejection. This
will enable ECP to be delivered safely to the ‘right’ patients
to obtain maximum efficacy. These recommendations are
intended to act as a guide for healthcare professionals who
are currently involved in providing ECP therapy or consider-
ing developing a service. This updated consensus statement
has benefited from further trials and expert knowledge from
the UKPS to deliver a statement that encourages a regime
which provides best response with minimal adverse events.
The recommendations are intended to act as a consensus
statement on best practice based on the current evidence
base on ECP and the opinions of the expert group. However,
it is recognised that any recommendations may need to be
revised in light of any new clinical findings on ECP.
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